MRNA-USA
 1/09/2020 MRNA-US BW   Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
 1/06/2020 MRNA-US BW   Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
12/11/2019 MRNA-US BW   Moderna Announces Key 2020 Investor and Analyst Events
"12/10/2019 MRNA-US BW   François Nader, M.D., Joins Moderna’s Board of Directors"
11/26/2019 MRNA-US BW   Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference
11/06/2019 MRNA-US BW   Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
11/05/2019 MRNA-US BW   Moderna to Present at Credit Suisse 28th Annual Healthcare Conference
10/24/2019 MRNA-US BW   Moderna Named Top Employer by Science for Fifth Consecutive Year
10/22/2019 MRNA-US BW   Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
"10/22/2019 MRNA-US BW   Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019"
10/02/2019 MRNA-US BW   Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019
 9/30/2019 MRNA-US BW   Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
 9/26/2019 MRNA-US BW   Harvard University Establishes mRna Immunotherapy Research Collaboration With Moderna
 9/26/2019 MRNA-US BW   Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University
 9/25/2019 MRNA-US BW   Moderna to Present at Upcoming Investor Conferences
 9/12/2019 MRNA-US BW   Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
 9/12/2019 MRNA-US BW   Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
 9/04/2019 MRNA-US BW   Moderna Appoints Tracey Franklin as Chief Human Resources Officer
" 8/29/2019 MRNA-US BW   Moderna to Host R&D Day on September 12, 2019"
 8/27/2019 MRNA-US BW   Moderna to Present at Upcoming Investor Conferences
 8/19/2019 MRNA-US BW   Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
 8/07/2019 MRNA-US BW   Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
" 7/24/2019 MRNA-US BW   Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019"
 7/10/2019 MRNA-US BW   Moderna to Present at ROTH RNA Revolution Conference
 6/18/2019 MRNA-US BW   Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
 6/07/2019 MRNA-US BW   Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
 6/01/2019 MRNA-US BW   Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
 5/17/2019 MRNA-US BW   Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
 5/10/2019 MRNA-US BW   Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
 5/08/2019 MRNA-US BW   Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates
 5/06/2019 MRNA-US BW   Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference
 4/29/2019 MRNA-US BW   Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
" 4/16/2019 MRNA-US BW   Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019"
 4/03/2019 MRNA-US BW   Moderna to Present at 18th Annual Needham Healthcare Conference
 3/06/2019 MRNA-US BW   Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress
 3/04/2019 MRNA-US BW   Moderna to Present at Upcoming Investor Conferences in March
" 2/21/2019 MRNA-US BW   Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019"
 2/20/2019 MRNA-US BW   Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic
 2/12/2019 MRNA-US BW   Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
 2/05/2019 MRNA-US BW   Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial
 1/30/2019 MRNA-US BW   Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors
 1/18/2019 MRNA-US BW   Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner
 1/08/2019 MRNA-US BW   Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives
 1/02/2019 MRNA-US BW   Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference
12/06/2018 MRNA-US BW   Moderna Announces Pricing of Initial Public Offering
#N/A
